Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Clareo Health | Lung Cancer Clinical Trials in Massachusetts | 755 Studies

Clinical Trials Lung CancerMassachusetts

Lung Cancer Clinical Trials in Massachusetts

Find 755 clinical trials for lung cancer near Massachusetts. Connect with research centers in your area.

All Lung Cancer trials nationwide All trials in Massachusetts

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 121-140 of 755 trials

RecruitingFiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLCThe purpose of this multicenter, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best…NCT06303505·Birmingham, Alabama and 28 others

Lung Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

TerminatedA Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.This single arm study in patients with advanced Stage IIIb/IV NSCLC who have progressive disease after deriving clinical benefit (defined as response or stable disease after 12…NCT00773383·Santa Monica, California and 15 others

TerminatedEvaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid TumorsThe objective of this study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M17D1 in patients with HER2-Expressing or HER2-Mutant Advanced or Metastatic…NCT06714617·Denver, Colorado and 8 others

CompletedA Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)This randomized, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with Tarceva (erlotinib) in…NCT01456325·Chandler, Arizona and 212 others

Active not recruitingPhase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC PatientsThis study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung…NCT05074810·Boulder, Colorado and 34 others

Active not recruitingStudy of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung CancerThe purpose of study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of Amivantamab as a monotherapy and in combination with lazertinib, and to determine the…NCT02609776·Duarte, California and 68 others

TerminatedA Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of ChemoimmunotherapyMetastatic lung cancer is the leading cause of cancer mortality worldwide with a 5-year survival of less than 5%.NCT04856176·Boston, Massachusetts

TerminatedHydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC)Erlotinib is a type of drug called a tyrosine kinase inhibitor (TKI). TKIs block a protein called epidermal growth factor receptor (EGFR).NCT01026844·Boston, Massachusetts

Not yet recruitingPhase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or MetastaticThis study is a first-in-human (FIH) Phase 1 open-label, multicenter study including three parts: * Part 1A is a dose escalation of STRO-006 monotherapy in selected tumor types…NCT07807345·La Jolla, California and 6 others

Active not recruitingTesting the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung CancerThis phase II trial compares cabozantinib alone and the combination of cabozantinib and nivolumab to standard chemotherapy in the treatment of patients with non-squamous non-small…NCT04310007·Birmingham, Alabama and 610 others

Approved for marketingExpanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) ActivationExpanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other…NCT03906331·Goodyear, Arizona and 63 others

TerminatedA Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive CancersThis study is designed to assess the safety and preliminary activity of SBT6050 in combination with trastuzumab deruxtecan (Part 1) or tucatinib plus trastuzumab +/- capecitabine…NCT05091528·Boston, Massachusetts

TerminatedEfficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in PhaseThis study is conducted in two phases.NCT02258607·Duarte, California and 4 others

CompletedA Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsThis is a first-in-human, open-label, dose escalation study to evaluate the safety and tolerability of pegilodecakin in participants with advanced solid tumors, dosed daily…NCT02009449·Los Angeles, California and 9 others

TerminatedA Phase 1b Trial of ATRC-101 in Adults With Advanced Solid MalignanciesATRC-101-A01 is a Phase 1b, open-label dose escalation and expansion trial of ATRC-101, an engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a…NCT04244552·Phoenix, Arizona and 18 others

CompletedStudying Tumor Tissue Samples From Patients With Early-Stage Non-Small Cell Lung CancerThis research trial studies biomarkers in predicting the risk of cancer returning after surgery in tissue samples of patients with early-stage non-small cell lung cancer.NCT01517971·Boston, Massachusetts

RecruitingPhase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsThe purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as…NCT06357533·Anchorage, Alaska and 288 others

TerminatedStudy to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) PatientsRociletinib is a novel, potent, small molecule irreversible tyrosine kinase inhibitor (TKI) that selectively targets mutant forms of the epidermal growth factor receptor (EGFR)…NCT01526928·Duarte, California and 48 others

CompletedSafety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung CancerMaintenance treatment of advanced stage squamous cell NSCLC.NCT02027428·Huntsville, Alabama and 118 others

TerminatedRadiation Therapy or Observation After Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung CancerRATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Sometimes, after chemotherapy, the tumor may not need more treatment until it progresses.NCT00776100·Scottsdale, Arizona and 167 others

PreviousPage 7 of 38Next

Other Conditions in Massachusetts

Breast Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma